ストックスクリーナーアプリを入手
1.43
4.03%
-0.06
前日終値:
$1.49
開ける：
$1.49
24時間の取引高:
76,983
Relative Volume:
0.13
時価総額：
$71.24M
収益：
$96.63M
当期純損益:
$-63.32M
株価収益率:
-0.9795
EPS:
-1.46
ネットキャッシュフロー:
$-54.55M
1週間 パフォーマンス:
-15.88%
1か月 パフォーマンス:
-13.33%
6か月 パフォーマンス:
-50.00%
1年 パフォーマンス:
-69.51%
1日の値動き範囲:
$1.385
$1.49
1週間の範囲:
$1.385
$1.78
52週間の値動き範囲:
$1.385
$4.69
Akoya Biosciences Inc Stock (AKYA) Company Profile
AKYA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.43 | 71.24M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
491.84 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.50 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
95.77 | 47.37B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
219.94 | 32.31B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.75 | 17.31B | 17.28B | 108.00M | 391.00M | 0.20 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-15 | ダウングレード | Craig Hallum | Buy → Hold |
| 2024-08-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-08-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | 開始されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-02-02 | 開始されました | UBS | Buy |
| 2022-11-03 | 開始されました | CapitalOne | Overweight |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-06-22 | 開始されました | BTIG Research | Buy |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-05-11 | 開始されました | Canaccord Genuity | Buy |
| 2021-05-11 | 開始されました | JP Morgan | Overweight |
| 2021-05-11 | 開始されました | Morgan Stanley | Overweight |
| 2021-05-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Akoya Biosciences Inc (AKYA) 最新ニュース
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - Marketscreener.com
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga India
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga India
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
Tikvah to oppose Quanterix-Akoya Biosciences merger By Investing.com - Investing.com Australia
Tikvah to oppose Quanterix-Akoya Biosciences merger - Investing.com India
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - Business Wire
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Marketscreener.com
Key Investor Fights Back: Quanterix Merger Under Fire Over Valuation Concerns - StockTitan
Akoya Biosciences Reports 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Akoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from Stephens - Defense World
Akoya Biosciences Shares Down 6.4% After Stock Offering… -June 08, 2023 at 10:10 am EDT - Marketscreener.com
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges - Investing.com Australia
Akoya: Q4 Earnings Snapshot - Milford Mirror
Akoya Biosciences earnings missed by $0.01, revenue topped estimates - Investing.com Australia
Akoya Biosciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Akoya Biosciences, Inc. SEC 10-K Report - TradingView
Kent Lake urges Quanterix to address questions regarding Akoya deal -March 17, 2025 at 04:28 pm EDT - Marketscreener.com
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Amid Pending Acquisition by Quanterix Corporation - Nasdaq
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results - GlobeNewswire
Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity - StockTitan
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger -March 11, 2025 at 10:40 am EDT - Marketscreener.com
Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns - StockTitan
Akoya climbs after merger deal with Quanterix - MSN
Piper Sandler Downgrades Akoya Biosciences to Neutral From Overweight, Adjusts Price Target to $2.40 From $3 - Marketscreener.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral - Investing.com
Piper Sandler cuts Akoya Biosciences stock rating to Neutral By Investing.com - Investing.com Canada
Quanterix Announces Acquisition of Akoya Biosciences - TipRanks
Quanterix Highlights Benefits Of Akoya Biosciences Acquisition -March 03, 2025 at 06:13 am EST - Marketscreener.com
Can Quanterix's Akoya Acquisition Transform Biomarker Detection and Deliver $1B Revenue? - StockTitan
Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Up 60.1% in February - Defense World
Akoya Biosciences (AKYA) to Release Earnings on Monday - MarketBeat
Akoya Biosciences’ Merger with Quanterix Moves Forward - Investing.com India
Quanterix advances towards Akoya Biosciences acquisition By Investing.com - Investing.com Australia
Akoya Biosciences' Merger with Quanterix Moves Forward By Investing.com - Investing.com South Africa
Quanterix advances towards Akoya Biosciences acquisition - Investing.com
Akoya Biosciences’ Merger with Quanterix Moves Forward By Investing.com - Investing.com UK
Akoya Biosciences stock hits 52-week low at $1.88 amid market challenges - Investing.com Australia
AKYA Stock Update: Akoya Biosciences Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Akoya Biosciences Inc (AKYA) 財務データ
収益
当期純利益
現金流量
EPS
Akoya Biosciences Inc (AKYA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
3.09%
0.06%
大文字化:
|
ボリューム (24 時間):